Get the Stockscreener App
1.8777
1.32%
-0.0223
Bioxcel Therapeutics Inc stock is traded at $1.8777, with a volume of 471.78K.
It is down -1.32% in the last 24 hours and down -25.89% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$1.90
Open:
$1.88
24h Volume:
471.78K
Relative Volume:
0.06
Market Cap:
$30.03M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.3058
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
-13.99%
1M Performance:
-25.89%
6M Performance:
+5.34%
1Y Performance:
+190.74%
1-Day Range:
$1.87
$2.00
1-Week Range:
$1.87
$2.18
52-Week Range:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.8755 | 37.33M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.56 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.13 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.17 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.47 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.40 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
New Haven’s BioXcel weathers turmoil to regain footing and market confidence - Hartford Business Journal
Why BioXcel Therapeutics Inc. stock remains on buy listsWeekly Trade Recap & Real-Time Stock Movement Alerts - newser.com
Can BioXcel Therapeutics Inc. stock beat market expectations this quarterAnalyst Downgrade & Daily Price Action Insights - newser.com
What dividend safety score for BioXcel Therapeutics Inc. stock2025 Sector Review & Fast Exit Strategy with Risk Control - newser.com
How analysts revise price targets for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Building trade automation scripts for BioXcel Therapeutics Inc.July 2025 Review & Entry Point Confirmation Signals - newser.com
BioXcel Therapeutics Inc Stock Analysis and ForecastMarket Timing Techniques & Build Wealth With Expert Timing Advice - earlytimes.in
Why BioXcel Therapeutics Inc. stock could see breakout soonJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Does BioXcel Therapeutics Inc. show high probability of reboundJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Published on: 2025-11-03 03:37:33 - newser.com
Will BioXcel Therapeutics Inc. stock benefit from automationPortfolio Value Summary & High Yield Stock Recommendations - newser.com
Published on: 2025-11-03 01:00:44 - newser.com
Published on: 2025-11-03 00:33:12 - newser.com
How BioXcel Therapeutics Inc. stock reacts to Fed rate cutsCEO Change & Weekly Return Optimization Alerts - newser.com
Tools to monitor BioXcel Therapeutics Inc. recovery probabilityQuarterly Earnings Summary & Fast Momentum Entry Tips - newser.com
Will BioXcel Therapeutics Inc. (BX20) stock recover faster than industry2025 Big Picture & Verified Entry Point Signals - newser.com
Why BioXcel Therapeutics Inc. stock remains a top recommendationGap Up & Low Risk Entry Point Guides - newser.com
Published on: 2025-11-02 05:48:35 - newser.com
Is BioXcel Therapeutics Inc. (BX20) stock bottoming after sell off2025 Market Outlook & Smart Swing Trading Alerts - newser.com
Published on: 2025-11-01 08:49:34 - newser.com
Can you recover from losses in BioXcel Therapeutics Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - newser.com
Leading vs lagging indicators on BioXcel Therapeutics Inc. performanceVolume Spike & Real-Time Stock Price Movement Reports - newser.com
BTAI sets Dec 12 virtual annual meeting; board backs all items - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
Will BioXcel Therapeutics Inc. benefit from macro trendsAnalyst Upgrade & Daily Profit Focused Stock Screening - newser.com
How BioXcel Therapeutics Inc. (BX20) stock reacts to stronger dollarBreakout Watch & Daily Chart Pattern Signal Reports - newser.com
Key metrics from BioXcel Therapeutics Inc.’s quarterly dataDay Trade & AI Enhanced Execution Alerts - newser.com
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):